Low-dose Buprenorphine Initiation of Opioid Use Disorder

• Status: Not yet recruiting
• Trial end date: 2027-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test whether low-dose buprenorphine initiation for treatment of opioid use disorder is safe and effective.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Montefiore Medical Center
• Treatments: Buprenorphine; Buprenorphine, Naloxone Drug Combination; Naloxone

Criteria

Inclusion Criteria:

• age ≥ 18 years

• opioid use disorder by DSM-V criteria

• currently using illicit opioids

• willingness to participate in low-dose BUP initiation or TAU protocols

• fluency in English or Spanish

Exclusion Criteria:

• receiving opioid agonist treatment in the past 30 days

• inability to provide informed consent

• unstable mental illness (e.g., suicidality, psychosis, etc.)

• moderate or severe alcohol use disorder or benzodiazepine use disorder by DSM-V criteria

• hypersensitivity to buprenorphine or naloxone.

• pregnancy (confirmed via urine testing)

• ineligible for private or public insurances